Analyzing the Effect of c-myc Oncogene and Matrix Mettalloproteinase-2 Enzyme Ekspression on Metastasis and Prognosis of Malignant Melanoma

Yıl 2016, Cilt: 7 Sayı: 3, 222 - 228, 01.09.2016

Abdulcebbar Siyer Yasemin Yuyucu Karabulut , Şakir Ünal Didem Derici

https://doi.org/10.5799/jcei.328612

Öz

Objectives: The aim of this study is to measure the effect of c-myc oncogene and matrix metalloproteinase-2 enzyme
expression on metastasis and prognosis of malignant melanoma. At the end of this study, we hope to get information
about the prognosis of melanoma, to be helpful for choosing the treatment strategy.
Methods: Sixty-three patients treated in our hospital during 2006-2015 were included in this study. All clinical and
histological parameters were collected from each patient’s records and survival rate is assessed. Forty-seven suitable
tumor specimens were assessed by immunohistochemical stains and analyzed for the c-myc and MMP-2 positivity. All
results were evaluated statistically for the effect on melanoma metastasis and survival rate.
Results: C-myc positivity and MMP-2 positivity decreases the survival rate of melanoma. MMP-2 positivity increases
the risk of death four more times.
Conclusions: So this study confirms that we can evaluate c-myc and MMP-2 as a prognostic factor. 

Anahtar Kelimeler

Malignant, melanoma, C-myc, Matrix metalloproteinase 2, oncogene, metastasis

Kaynakça

• 1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
• 2. Linos E, Swetter SM, Cockburn MG, et al. Increasing burden of melanoma in the United States. J Invest Dermatol 2009; 129:1666-1674.
• 3. Siegel R, Zou Z, Jemal A, et al. Cancer Statistics, 2014. CA: A Cancer J Clinician 2014; 64:9-29.
• 4. Lotze MT. Keystone symposium: Melanoma and the biology of the neural crest. Melanoma Res 1992; 2:131.
• 5. Erdmann F, Lortet‐Tieulent J, Schüz J, et al. International trends in the incidence of malignant melanoma 1953-2008-are recent generations at higher or lower risk? Int J Cancer 2013; 132: 385-400.
• 6. American Cancer Society, American Cancer Society facts and figures. American Cancer Society, Atlanta, 1998.
• 7. Turpeenniemi-Hujanen, T: Gelatinases [MMP-2 and-9] and their natural inhibitors as prognostic indicators in solid cancers: Biochimie 2005; 87:287-297.
• 8. Laing J, Rew D, Wilson G. Cell kinetics of human solid tumours. BJR supplement/BIR: 1992; 24:163.
• 9. Vaisanen A, Kuvaja P, Kallioinen M, et al. A prognostic index in skin melanoma through the combination of matrix metalloproteinase-2, Ki67, and p53. Human Pathol 2011; 42:1103-1111.
• 10. Ramsden A, Grover R, Chana J, et al. A prospective analysis of c-myc oncoprotein levels as a prognostic marker in malignant melanoma. J Plast Reconstruct Aesth Surg 2007; 60:. 626-630.
• 11. Väisänen AH, Kallioinen M, Turpeenniemi-Hujanen T. Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma. Human Pathol 2008; 39: 377-385.
• 12. Ross D, Laing JHE, Sanders R, et al. Long term follow-up of c-myc, p53 and proliferation measurements in malignant melanoma. Europ J Surgl Oncol 2006; 32:80-84.
• 13. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Eng J Med 2011;364:2507-2516.